To evaluate the efficacy, safety and adverse reactions of "TAE combined with hepatic arterial infusion of tislelizumab + bevacizumab" as the first-line treatment for hepatocellular carcinoma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 29e629b27e7a2580f90084423cdf62a170fe0699
First added on: Oct 10, 2026